T44.5X2A Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter

Name of the Condition

• Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter

Summary

This code describes poisoning resulting from intentional self-harm involving predominantly beta-adrenoreceptor agonists, with "initial encounter" indicating the first episode of care. Beta-adrenoreceptor agonists are medications that stimulate beta-adrenergic receptors, affecting heart rate, blood pressure, and airway function. Intentional self-harm cases involve deliberate exposure to these substances, leading to adverse physiological responses.

Causes

Intentional self-harm poisoning may result from deliberate ingestion or administration of beta-adrenoreceptor agonists. The underlying cause is self-directed harm, often associated with psychological distress or suicidal intent. The specific agent, dosage, and route of exposure influence the severity of the poisoning.

Risk Factors

• History of mental health conditions (e.g., depression, anxiety).
• Prior suicide attempts or self-harm behaviors.
• Access to beta-adrenoreceptor agonists (e.g., prescription medications).
• Substance use disorders involving related agents.
• Social or environmental stressors contributing to self-harm.

Symptoms

• Tachycardia or arrhythmias.
• Hypertension or hypotension.
• Tremors, anxiety, or restlessness.
• Headache, dizziness, or syncope.
• Nausea, vomiting, or abdominal pain.
• Shortness of breath or bronchospasm.
• Chest pain or palpitations.

Diagnosis

Diagnosis requires clinical evaluation of symptoms, patient history (including self-harm intent), and toxicology screening. Laboratory tests may assess drug levels, electrolytes, and organ function. Imaging or cardiac monitoring may be used to evaluate complications like arrhythmias or myocardial injury.

Treatment Options

Treatment focuses on stabilizing the patient, reversing toxicity, and addressing self-harm. Interventions may include activated charcoal (if appropriate), beta-blockers for tachyarrhythmias, and supportive care (e.g., fluids, oxygen). Psychiatric evaluation and crisis intervention are critical for ongoing management.

Prognosis and Follow-Up

Prognosis depends on the dose, agent, and timeliness of care. Early intervention improves outcomes, but severe cases may involve cardiac or respiratory complications. Follow-up includes monitoring for recurrence, psychiatric support, and safety planning to prevent future self-harm.

Complications

• Cardiac arrhythmias or myocardial infarction.
• Respiratory distress or bronchospasm.
• Metabolic disturbances (e.g., hypokalemia).
• Neurological effects (e.g., seizures, coma).
• Long-term psychological sequelae.

Lifestyle & Prevention

Prevention involves secure storage of medications, education on safe use, and addressing underlying mental health concerns. Support systems (e.g., counseling, crisis hotlines) reduce self-harm risk. Family or caregivers should be aware of warning signs and access to help.

When to Seek Professional Help

Seek immediate care for suspected self-harm, overdose, or severe symptoms (e.g., chest pain, difficulty breathing). Emergency services or mental health professionals should be contacted if self-harm intent is suspected, even without obvious symptoms.

Tips for Medical Coders

Document the intent (intentional self-harm), encounter type (initial), and specific agent when available. Ensure clinical notes support the diagnosis and intent. Use this code only for initial encounters; subsequent care uses different encounter codes. Verify that the poisoning is attributed to predominantly beta-adrenoreceptor agonists.